M3, Inc. (TYO:2413)
Japan · Delayed Price · Currency is JPY 2,648.00
+65.50 (2.54%)
Nov 26, 2025, 2:55 PM JST
M3, Inc. Revenue
M3, Inc. had revenue of 84.69B JPY in the quarter ending September 30, 2025, with 39.72% growth. This brings the company's revenue in the last twelve months to 330.97B, up 33.50% year-over-year. In the fiscal year ending March 31, 2025, M3, Inc. had annual revenue of 284.90B with 19.26% growth.
Revenue (ttm)
330.97B
Revenue Growth
+33.50%
P/S Ratio
5.29
Revenue / Employee
21.55M
Employees
15,360
Market Cap
1.75T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 284.90B | 46.02B | 19.26% |
| Mar 31, 2024 | 238.88B | 8.07B | 3.49% |
| Mar 31, 2023 | 230.82B | 22.66B | 10.89% |
| Mar 31, 2022 | 208.16B | 38.96B | 23.03% |
| Mar 31, 2021 | 169.20B | 38.23B | 29.19% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Takeda Pharmaceutical Company | 4.42T |
| Otsuka Holdings | 2.42T |
| Astellas Pharma | 2.01T |
| Daiichi Sankyo Company | 1.98T |
| Chugai Pharmaceutical | 1.21T |
| Terumo | 1.06T |
| Olympus | 977.65B |
| HOYA Corporation | 892.50B |